Pfizer: Buy This Big Yielder On The Strong Pipeline

ProArtWork Pfizer's (NYSE:PFE) cash flow from operations in 2022, driven by sales of the company's COVID-19 vaccine and Paxlovid, hit $29.267 billion. Fast-forward to 2023, and with COVID largely behind us, revenue from those products plummeted, pushing cash flow from operations down to$8.7 billion. With that in mind, it's not difficult to understand why the stock fell by roughly 23% over the last year. But there is more to Pfizer than coronavirus meds. The firm has a solid drug pipeline, and in an industr ...